Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 26.5
(1.73%)
SEK 26.5
(1.73%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 181.73 Million SEK | 38.32% |
| 2022 | 131.38 Million SEK | 35.51% |
| 2021 | 96.95 Million SEK | 80.73% |
| 2020 | 53.64 Million SEK | 17.24% |
| 2019 | 45.75 Million SEK | 99.66% |
| 2018 | 22.91 Million SEK | 29.02% |
| 2017 | 17.76 Million SEK | 60.82% |
| 2016 | 11.04 Million SEK | 5.84% |
| 2015 | 10.43 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 64.63 Million SEK | 19.64% |
| 2024 Q2 | 51.46 Million SEK | -16.34% |
| 2023 FY | 200.63 Million SEK | 52.71% |
| 2023 Q3 | 39.23 Million SEK | -23.46% |
| 2023 Q1 | 35.38 Million SEK | -34.34% |
| 2023 Q2 | 51.26 Million SEK | 44.85% |
| 2023 Q4 | 54.02 Million SEK | 37.7% |
| 2022 FY | 131.38 Million SEK | 35.51% |
| 2022 Q4 | 53.89 Million SEK | 85.89% |
| 2022 Q2 | 29.2 Million SEK | 51.48% |
| 2022 Q3 | 28.99 Million SEK | -0.74% |
| 2022 Q1 | 19.28 Million SEK | -62.4% |
| 2021 Q1 | 14.17 Million SEK | -8.42% |
| 2021 FY | 96.95 Million SEK | 80.73% |
| 2021 Q2 | 17.28 Million SEK | 21.94% |
| 2021 Q3 | 14.2 Million SEK | -17.82% |
| 2021 Q4 | 51.27 Million SEK | 260.9% |
| 2020 Q4 | 15.48 Million SEK | 31.08% |
| 2020 FY | 53.64 Million SEK | 17.24% |
| 2020 Q3 | 11.81 Million SEK | -24.47% |
| 2020 Q2 | 15.63 Million SEK | 45.97% |
| 2020 Q1 | 10.71 Million SEK | -28.85% |
| 2019 Q2 | 11.38 Million SEK | 32.11% |
| 2019 Q1 | 8.61 Million SEK | 130.72% |
| 2019 Q3 | 10.7 Million SEK | -5.95% |
| 2019 FY | 45.75 Million SEK | 99.66% |
| 2019 Q4 | 15.05 Million SEK | 40.66% |
| 2018 Q4 | 3.73 Million SEK | -40.94% |
| 2018 Q1 | 4.51 Million SEK | -23.28% |
| 2018 FY | 22.91 Million SEK | 29.02% |
| 2018 Q2 | 8.34 Million SEK | 84.81% |
| 2018 Q3 | 6.32 Million SEK | -24.23% |
| 2017 Q4 | 5.88 Million SEK | 42.95% |
| 2017 Q1 | 3.26 Million SEK | -0.82% |
| 2017 Q2 | 4.49 Million SEK | 37.38% |
| 2017 FY | 17.76 Million SEK | 60.82% |
| 2017 Q3 | 4.11 Million SEK | -8.33% |
| 2016 Q1 | 2.4 Million SEK | 0.0% |
| 2016 FY | 11.04 Million SEK | 5.84% |
| 2016 Q3 | 2.94 Million SEK | 22.46% |
| 2016 Q4 | 3.29 Million SEK | 12.03% |
| 2016 Q2 | 2.4 Million SEK | 0.0% |
| 2015 FY | 10.43 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | -370.302% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 43.474% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 49.183% |
| Xintela AB (publ) | 57.31 Million SEK | -217.074% |
| Active Biotech AB (publ) | 44.8 Million SEK | -305.575% |
| Amniotics AB (publ) | 29.07 Million SEK | -525.117% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -1140.251% |
| BioArctic AB (publ) | 89.62 Million SEK | -102.767% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 87.998% |
| Camurus AB (publ) | 1.05 Billion SEK | 82.85% |
| Cantargia AB (publ) | 290.01 Million SEK | 37.337% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -730.025% |
| CombiGene AB (publ) | 44.14 Million SEK | -311.684% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -27.098% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -541.572% |
| Genovis AB (publ.) | 88.19 Million SEK | -106.055% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -57.929% |
| Mendus AB (publ) | 129.13 Million SEK | -40.73% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -2400.468% |
| Intervacc AB (publ) | 79.78 Million SEK | -127.78% |
| Kancera AB (publ) | 63.07 Million SEK | -188.115% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -3192.879% |
| LIDDS AB (publ) | 27.75 Million SEK | -554.85% |
| Lipum AB (publ) | 37.3 Million SEK | -387.131% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -2405.294% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -33.714% |
| NextCell Pharma AB | -576.01 Thousand SEK | 31650.001% |
| OncoZenge AB (publ) | 15.9 Million SEK | -1042.622% |
| Saniona AB (publ) | 1.07 Million SEK | -16774.095% |
| Ziccum AB (publ) | 27.87 Million SEK | -551.89% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -1008.067% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 40.821% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -326.285% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -927.733% |
| Corline Biomedical AB | 30.16 Million SEK | -502.407% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -213.167% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -118.512% |
| Aptahem AB (publ) | 10.01 Million SEK | -1714.991% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -34.924% |
| Fluicell AB (publ) | 28.61 Million SEK | -535.056% |
| Biovica International AB (publ) | 133.72 Million SEK | -35.904% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -818.312% |
| AcouSort AB (publ) | 25.87 Million SEK | -602.326% |
| Abliva AB (publ) | 27.86 Million SEK | -552.171% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 6.081% |
| 2cureX AB (publ) | 36.51 Million SEK | -397.656% |
| I-Tech AB | 40.14 Million SEK | -352.66% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 78.855% |
| Cyxone AB (publ) | 28.21 Million SEK | -544.127% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -66.167% |
| Biosergen AB | 26.8 Million SEK | -577.884% |
| Nanologica AB (publ) | 69.88 Million SEK | -160.04% |
| SynAct Pharma AB | 224.49 Million SEK | 19.048% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -311.386% |
| BioInvent International AB (publ) | 441.4 Million SEK | 58.828% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -658.671% |
| Alzinova AB (publ) | 36.39 Million SEK | -399.324% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 37.278% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -2213.235% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -63.851% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -1136.286% |